The JADE study will be evaluating BI 1584862, an investigational oral compound that targets inflammation and preserves ...

We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer ...

Clinical Trials in India have gained global attention for their rapid growth, world-class infrastructure, and access to a diverse patient population. With increasing support from regulatory bodies and ...

IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

A potential game changer in the treatment of retinal disease, the novel dual-target drug shows encouraging results.

Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity, ...

The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network caught up with Jogin Desai. Dr. Desai is the founder of Eyestem Research, a biotechnology ...

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb ...

Dr. Scott T. Tagawa discusses what patients with prostate cancer should know about the potential benefits and risks of ...